Vanderbilt University Medical Center, Nashville, TN, USA.
Minneapolis Heart Institute, Abbott Northwestern Hospital and Minneapolis Heart Institute Foundation, 920 E 28th Street #300, Minneapolis, MN, 55407, USA.
Curr Cardiol Rep. 2019 Mar 4;21(4):17. doi: 10.1007/s11886-019-1102-3.
We provide a concise update on the contemporary management of cardiogenic shock in the setting of acute coronary syndrome (ACS). Early shock recognition, optimal selection and initiation of mechanical circulatory support (MCS), early coronary revascularization, and a team-based, protocol-driven approach are the current pillars of management.
Cardiogenic shock complicates approximately 5-10% of ACS cases and continues to have high mortality. Early use of mechanical circulatory may prevent the downward spiral of shock and has significantly increased over time, supported mainly by registry data. In the CULPRIT-SHOCK trial, culprit-only revascularization was associated with a lower 30-day incidence of all-cause death or severe renal failure, compared with immediate multivessel PCI. Routine revascularization of non-infarct related artery lesion(s) during primary PCI for cardiogenic shock is, therefore, not recommended. The routine use of an intra-aortic balloon pump (IABP) was not associated with improved outcomes in the IABP-SHOCK II trial. A team-based and protocol-driven approach may further improve outcomes. Recent advances in coronary revascularization and use of MCS, implementation of shock teams and standardized protocols may improve outcomes of cardiogenic shock in ACS patients.
本文就急性冠脉综合征(ACS)并发心原性休克的当代治疗进行简要更新。早期休克识别、最佳机械循环支持(MCS)的选择和启动、早期冠状动脉血运重建以及以团队为基础、基于方案的治疗方法是目前治疗的主要支柱。
心原性休克约占 ACS 病例的 5-10%,死亡率仍然很高。早期使用机械循环辅助可能会阻止休克的恶化,并且随着时间的推移,机械循环辅助的使用显著增加,主要得到了注册数据的支持。在 CULPRIT-SHOCK 试验中,与即刻多血管 PCI 相比,罪犯血管血运重建与 30 天全因死亡率或严重肾功能衰竭发生率降低相关。因此,不推荐在原发性 PCI 治疗心原性休克时常规血运重建非梗死相关动脉病变。在 IABP-SHOCK II 试验中,主动脉内球囊反搏(IABP)的常规使用并未改善预后。基于团队和基于方案的方法可能进一步改善预后。冠状动脉血运重建和 MCS 的应用、休克团队的实施和标准化方案的实施可能会改善 ACS 患者心原性休克的预后。